A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Alliance Foundation Trials, LLC
Start Date
November 17, 2017
End Date
April 30, 2025
Administered By
Duke Cancer Institute
Awarded By
Alliance Foundation Trials, LLC
Start Date
November 17, 2017
End Date
April 30, 2025